Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the Connexa Pharmaceuticals first quarter 2025 earnings conference call. At this time, all participants are on a listen only mode. After the speaker's presentation, there will be a question and answer session. To ask a question, During the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Jonathan Kirschenbaum, Investor Relations. Please go ahead. Thank you, Operator. Good morning, everyone, and thank you for joining Connexa's call to discuss our first quarter 2025 financial results and recent portfolio execution. A press release highlighting these results can be found on our website under the Investors section. As for the agenda for today's call, our Chief Executive Officer, Sanj K. Patel, will begin with an introduction. Ross Mote, our Chief Commercial Officer, will provide an update on ARCWIS commercial execution. Then Mark Ragosa, our Chief Financial Officer, will review our first quarter 2025 financial results. Finally, Sanj will share closing remarks and kick off the Q&A session, for which Dr. John Paolini, our Chief Medical Officer, and Evan Tesari, our Chief Operating Officer, will also be on the line. Before getting started, Please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements. A review of such statements and risk factors can be found on this slide, as well as under the caption, Risk Factors, contained in our SEC...